| Consensus Recommendations for Severe Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Consensus recommendations for severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia |
|
Biol Blood Marrow Transplant |
Aplastic Anemia |
| Considerations for Drug Development in Myelodysplastic Syndromes |
|
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Controversies on the Consequences of Iron Overload and Chelation in MDS |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
|
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
